Kayla M. Teopiz

Kayla M. Teopiz

Auto-generated profile, based on publicly available information

Kayla M. Teopiz

Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
DADania Akbar
Dania Akbar
GRGreg Rhee
Greg Rhee
FCFelicia Ceban
Felicia Ceban
Roger HoRoger Ho
Roger Ho
KTKayla M. Teopiz
Kayla M. Teopiz
RMRoger McIntyre
Roger McIntyre

22 September 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ZLZiyi Lin
Ziyi Lin
LCLu Cheng
Lu Cheng
XHXue Han
Xue Han
HWHongqiong Wang
Hongqiong Wang
YLYuhua Liao
Yuhua Liao
RMRoger McIntyre
Roger McIntyre
Background: Many people living with major depressive disorder (MDD) in China do not receive treatment owing to a lack of mental health services, along with significant stigma toward mental illness. Internet-based cognitive behavioral therapy (ICBT) has been proposed to increase access to mental health care for people with MDD. Objective: The aims of this study were to (1) evaluate the efficacy of ICBT for depressive symptoms in patients with MDD; (2) evaluate the effect of ICBT on anxiety symptoms, nonspecific psychological distress, general self-efficacy, depression stigma, social function, and health-related quality of life (HRQoL); and (3) explore the acceptability of and satisfaction with the ICBT program among participants. Methods: Patients with MDD were enrolled and randomized to the ICBT group or the waiting-list control (WLC) group. The ICBT group received ICBT delivered through a WeChat mini-program with general support by nonspecialists. Participants in the 2 groups were self-evaluated online at baseline and posttreatment for changes in the primary outcome (ie, depressive symptoms) and secondary outcomes (ie, anxiety symptoms, nonspecific psychological distress, general self-efficacy, depression stigma, social functional impairment, and HRQoL). Changes in outcomes were measured by changes in overall scores on respective scales, and response and remission rates were calculated based on depressive symptoms. The acceptability of and satisfaction with the ICBT program were measured by treatment adherence and participants’ feelings (ie, modules seriously completed, perceived benefit, and satisfaction). Results: We included 40 patients who were randomly assigned to the ICBT group and 44 who were assigned to the WLC group. Compared with the WLC group, the ICBT group had fewer depressive symptoms, fewer anxiety symptoms, less nonspecific psychological distress, and greater general self-efficacy. Moreover, the ICBT group had higher response (18/31, 58%) and remission rates (17/31, 55%). The adherence rate in the ICBT group was 78% (31/40), and the majority of participants who completed all ICBT modules were satisfied with the ICBT program. Conclusions: ICBT demonstrated greater improvements in depressive symptoms, anxiety symptoms, nonspecific psychological distress, and general self-efficacy among selected patients with MDD in comparison with the findings in waiting-list controls. The ICBT program in this study had good acceptability and satisfaction among participants. Trial Registration: Chinese Clinical Trial Registry (ChiCTR2100046425); https://tinyurl.com/bdcrj4zv

Agata Ewa Chudzicka-CzupałaAgata Ewa Chudzicka-Czupała
Agata Ewa Chudzicka-Czupała
SCSoon Kiat Chiang
Soon Kiat Chiang
Damian Wojciech GrabowskiDamian Wojciech Grabowski
Damian Wojciech Grabowski
MŻMarta Żywiołek-Szeja
Marta Żywiołek-Szeja
MQMatthew Quek
Matthew Quek
RMRoger McIntyre
Roger McIntyre
Background: Since the onset of COVID-19, public health policies and public opinions changed from stringent preventive measures against spread of COVID-19 to policies accommodating life with continued, diminished risk for contracting COVID-19. Poland is a country that demonstrated severe psychological impact and negative mental health. The study aims to examine psychological impact and changes in levels of depression, anxiety, and stress among three cross-sectional samples of Polish people and COVID-19-related factors associated with adverse mental health. Methods: In total, 2324 Polish persons participated in repeated cross-sectional studies across three surveys: Survey 1 (22 to 26 March 2020), Survey 2 (21 October to 3 December 2020), and Survey 3 (3 November to 10 December 2021). Participants completed an online survey, including Impact of Event Scale-Revised (IES-R), Depression, Anxiety, and Stress Scale (DASS-21), demographics, knowledge, and concerns of COVID-19 and precautionary measures. Results: A significant reduction of IES-R scores was seen across surveys, while DASS-21 scores were significantly higher in Survey 2. There was significant reduction in the frequency of following COVID-19 news, recent COVID-19 testing, and home isolation from Survey 1 to 3. Being emale was significantly associated with higher IES-R and DASS-21 scores in Surveys 1 and 2. Student status was significantly associated with higher DASS-21 across surveys. Chills, myalgia, and fatigue were significantly associated with high IES-R or DASS-21 scores across surveys. Frequency of wearing masks and perception that mask could reduce risk of COVID-19 were significantly associated with higher IES-R and DASS-21 scores. Conclusion: Conclusions: The aforementioned findings indicate a reduction in the level of the measured subjective distress andin the frequency of checking COVID-19 news-related information across three periods during the pandemic in Poland.

28 November 2025 in Journal of Affective Disorders
Verified
Journal Article
Open access
SWSabrina Wong
Sabrina Wong
GLGia Han Le
Gia Han Le
HGHernan F Guillen-Burgos
Hernan F Guillen-Burgos
RHRoger C. Ho
Roger C. Ho
BCBing Cao
Bing Cao
RMRoger McIntyre
Roger McIntyre
Persons with depression are differentially affected by metabolic alterations, notably, insulin resistance and dyslipidemia. Metabolic alterations affect acute pharmacotherapy response and predispose risk for cardiovascular diseases. We aimed to extend knowledge pertaining to the depression-metabolic alteration association by evaluating whether depressive symptom severity moderates the association. We conducted a systematic search of PubMed, Ovid and Scopus from inception to May 2025. Two reviewers (S.W. and G.H.L.) independently screened the identified studies. Studies were included if they enrolled adults with depression and reported on at least one metabolic parameter (i.e., fasting glucose, insulin, lipid panels). Standardized mean differences of metabolic parameters were pooled across studies. We identified 28 studies for inclusion. Persons with depression exhibited higher fasting glucose (SMD = 0.30, 95 % CI [0.12, 0.48]) and dyslipidemia [i.e., trends of increased low-density lipoprotein (SMD = 0.21, 95 % CI [-0.03, 0.44]) and lower high-density lipoprotein (SMD = -0.72, 95 % CI [-1.41, -0.03])]. Measures of insulin resistance were positively associated with anhedonia severity, sleep disturbances, and suicidal ideation. Between-study methodological differences, including study design and sociodemographics, affects the synthesis of overall trends. Herein, we identify an association between depressive symptom severity and dysglycemia, dyslipidemia and insulin resistance. The results augment the conceptual framework implicating metabolic disturbances in depression pathophysiology and indirectly support testing that therapeutics currently in development in the treatment of depression (e.g., GLP-1 receptor agonists) may exhibit differential efficacy as a function of illness severity.

22 April 2025 in Journal of Affective Disorders
Verified
Journal Article
Open access
MCMorgan C.H. Cheng
Morgan C.H. Cheng
CDChristine E. Dri
Christine E. Dri
HBHana Ballum
Hana Ballum
KVKyle Valentino
Kyle Valentino
WCWilliam Cheung
William Cheung
RMRoger McIntyre
Roger McIntyre
The rapid and clinically meaningful antidepressant effects of ketamine and esketamine are well-established in major depressive disorder (MDD) and treatment-resistant depression (TRD) as evidenced by improvement in clinician- and patient-reported depression measures. However, there remains a need to determine how these agents affect patient-reported quality of life (QoL). Herein, we aimed to systematically review extant studies evaluating the effect of ketamine and esketamine on QoL measures. A literature search was conducted on online databases (PubMed, Scopus, Web of Science, Medline, and clinicaltrials.gov) for articles from inception to September 30th, 2024, reporting on the association between ketamine/esketamine and measures of QoL in persons diagnosed with MDD or TRD. A risk of bias assessment was conducted using the ROBINS-1 tool and the Newcastle-Ottawa Scale. Five studies were identified that investigated the association between ketamine/esketamine and measures of QoL in persons with MDD or TRD. Scales used to measure QoL included the WHOQOL-BREF scale, Assessment of Quality of Life 8D test, and the EuroQol-5 Dimension-5 Layers. Statistically significant findings (p < 0.001) suggest that ketamine and esketamine improve measures of QoL in persons with MDD or TRD. However, an overall moderate risk of bias was observed in the papers included in this analysis. Extant studies suggest that ketamine and esketamine treatment are associated with improvement in QoL measures in adults with MDD or TRD. Limitations of this study include hetergeneity in the types of QoL scales as well as study study duration among the studies included. Near-term research priorities should endeavour to investigate the effect of ketamine and esketamine on specific domains of QoL, respectively.